Literature DB >> 26412386

The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma.

Shiyuan Song1, Ying Wang1, Po Xu2, Ruina Yang1, Zhikun Ma1, Shuo Liang1, Guangping Zhang1.   

Abstract

Histone deacetylase 8 (HDAC8), a unique member of class I HDACs, shows remarkable correlation with advanced disease stage. The depletion of HDAC8 leads to inhibition of proliferation, apoptosis and cell cycle arrest in multiple malignant tumors. However, little is known about the contribution of HDAC8 to the tumorigenesis of gastric cancer (GC). The present study investigated expression of HDAC8 in GC cell lines and tissues, and the roles of HDAC8 inhibition in the proliferation, cell cycle and apoptosis of gastric cancer cells and explored the potential mechanisms. In the present study, quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), western blotting, and immunohistochemistry were used to examine the mRNA and protein expression of HDAC8 in GC cell lines and tissues. Then, the correlation between the clinicopathological parameters and the expression of HDAC8 was assessed. Finally, siRNA transfection and HDAC8 plasmid was performed to explore the functions of HDAC8 in GC progression in vitro. We found that the expression of HDAC8 was significantly upregulated both in GC cell lines and tumor tissues compared to human normal gastric epithelial cell, GES-1 and matched non-tumor tissues. Furthermore, depletion of HDAC8 remarkably inhibited GC cell proliferation, increased the apoptosis rate and G0/G1 phase percentage in vitro. Western blotting showed that the expression of protein promoting apoptosis such as, Bmf, activated caspase-3, caspase-6 were elevated following HDAC8 depletion. Our data exhibited an important role of HDAC8 in promoting gastric cancer tumorigenesis and identify this HDAC8 as a potential therapeutic target for the treatment of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26412386     DOI: 10.3892/ijo.2015.3182

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation.

Authors:  Neha Upadhyay; Kalpana Tilekar; Niklas Jänsch; Markus Schweipert; Jessica D Hess; Luca Henze Macias; Piotr Mrowka; Renato J Aguilera; Jun-Yong Choe; Franz-Josef Meyer-Almes; C S Ramaa
Journal:  Bioorg Chem       Date:  2020-05-15       Impact factor: 5.275

Review 2.  Pathological Role of HDAC8: Cancer and Beyond.

Authors:  Ji Yoon Kim; Hayoung Cho; Jung Yoo; Go Woon Kim; Yu Hyun Jeon; Sang Wu Lee; So Hee Kwon
Journal:  Cells       Date:  2022-10-09       Impact factor: 7.666

3.  Expression and prognostic analyses of HDACs in human gastric cancer based on bioinformatic analysis.

Authors:  Luting Chen; Yuchang Fei; Yurong Zhao; Quan Chen; Peifeng Chen; Lei Pan
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

Review 4.  Epigenetic roles in the malignant transformation of gastric mucosal cells.

Authors:  Jun Tie; Xiangyuan Zhang; Daiming Fan
Journal:  Cell Mol Life Sci       Date:  2016-07-27       Impact factor: 9.261

5.  Effect of Sodium Butyrate on LHX1 mRNA Expression as a Transcription Factor of HDAC8 in Human Colorectal Cancer Cell Lines.

Authors:  Mahsa Ghiaghi; Flora Forouzesh; Hamzeh Rahimi
Journal:  Avicenna J Med Biotechnol       Date:  2019 Oct-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.